Literature DB >> 23262201

Synthesis and evaluation of a backbone biodegradable multiblock HPMA copolymer nanocarrier for the systemic delivery of paclitaxel.

Rui Zhang1, Kui Luo, Jiyuan Yang, Monika Sima, Yongen Sun, Margit M Janát-Amsbury, Jindřich Kopeček.   

Abstract

The performance and safety of current antineoplastic agents, particularly water-insoluble drugs, are still far from satisfactory. For example, the currently widely used Cremophor EL®-based paclitaxel (PTX) formulation exhibits pharmacokinetic concerns and severe side effects. Thus, the concept of a biodegradable polymeric drug-delivery system, which can significantly improve therapeutic efficacy and reduce side effects is advocated. The present work aims to develop a new-generation of long-circulating, biodegradable carriers for effective delivery of PTX. First, a multiblock backbone biodegradable N-(2-hydroxypropyl)methacrylamide(HPMA) copolymer-PTX conjugate (mP-PTX) with molecular weight (Mw) of 335 kDa was synthesized by RAFT (reversible addition-fragmentation chain transfer) copolymerization, followed by chain extension. In vitro studies on human ovarian carcinoma A2780 cells were carried out to investigate the cytotoxicity of free PTX, HPMA copolymer-PTX conjugate with Mw of 48 kDa (P-PTX), and mP-PTX. The experiments demonstrated that mP-PTX has a similar cytotoxic effect against A2780 cells as free PTX and P-PTX. To further compare the behavior of this new biodegradable conjugate (mP-PTX) with free PTX and P-PTX in vivo evaluation was performed using female nu/nu mice bearing orthotopic A2780 ovarian tumors. Pharmacokinetics study showed that high Mw mP-PTX was cleared more slowly from the blood than commercial PTX formulation and low Mw P-PTX. SPECT/CT imaging and biodistribution studies demonstrated biodegradability as well as elimination of mP-PTX from the body. The tumors in the mP-PTX treated group grew more slowly than those treated with saline, free PTX, and P-PTX (single dose at 20 mg PTX/kg equivalent). Moreover, mice treated with mP-PTX had no obvious ascites and body-weight loss. Histological analysis indicated that mP-PTX had no toxicity in liver and spleen, but induced massive cell death in the tumor. In summary, this biodegradable drug delivery system has a great potential to improve performance and safety of current antineoplastic agents.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23262201      PMCID: PMC3565036          DOI: 10.1016/j.jconrel.2012.12.009

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  44 in total

1.  Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice.

Authors:  A Cirstoiu-Hapca; F Buchegger; N Lange; L Bossy; R Gurny; F Delie
Journal:  J Control Release       Date:  2010-02-25       Impact factor: 9.776

2.  Near-infrared light triggers release of Paclitaxel from biodegradable microspheres: photothermal effect and enhanced antitumor activity.

Authors:  Jian You; Ruping Shao; Xin Wei; Sanjay Gupta; Chun Li
Journal:  Small       Date:  2010-05-07       Impact factor: 13.281

3.  Proapoptotic lipid nanovesicles: synergism with paclitaxel in human lung adenocarcinoma A549 cells.

Authors:  Nitin Joshi; Thanigaivel Shanmugam; Anubhav Kaviratna; Rinti Banerjee
Journal:  J Control Release       Date:  2011-07-23       Impact factor: 9.776

4.  A novel polymer-paclitaxel conjugate based on amphiphilic triblock copolymer.

Authors:  Zhigang Xie; Huili Guan; Xuesi Chen; Changhai Lu; Li Chen; Xiuli Hu; Quan Shi; Xiabin Jing
Journal:  J Control Release       Date:  2006-11-23       Impact factor: 9.776

5.  HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activity.

Authors:  Tomáš Etrych; Vladimír Subr; Jiří Strohalm; Milada Sírová; Blanka Ríhová; Karel Ulbrich
Journal:  J Control Release       Date:  2012-06-30       Impact factor: 9.776

6.  Hyaluronan oligomers-HPMA copolymer conjugates for targeting paclitaxel to CD44-overexpressing ovarian carcinoma.

Authors:  Gal Journo-Gershfeld; Dana Kapp; Yosi Shamay; Jindřich Kopeček; Ayelet David
Journal:  Pharm Res       Date:  2012-02-16       Impact factor: 4.200

7.  Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial.

Authors:  R S Keresztes; J L Port; M W Pasmantier; R J Korst; N K Altorki
Journal:  J Thorac Cardiovasc Surg       Date:  2003-11       Impact factor: 5.209

8.  Hypersensitivity reactions from taxol.

Authors:  R B Weiss; R C Donehower; P H Wiernik; T Ohnuma; R J Gralla; D L Trump; J R Baker; D A Van Echo; D D Von Hoff; B Leyland-Jones
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

Review 9.  Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate.

Authors:  Stewart D Chipman; Fred B Oldham; Gabriella Pezzoni; Jack W Singer
Journal:  Int J Nanomedicine       Date:  2006

Review 10.  First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence.

Authors:  J Sandercock; M K B Parmar; V Torri; W Qian
Journal:  Br J Cancer       Date:  2002-10-07       Impact factor: 7.640

View more
  27 in total

1.  Investigation into the Biological Impact of Block Size on Cathepsin S-Degradable HPMA Copolymers.

Authors:  Wei Fan; Wenting Zhang; Yinnong Jia; Susan K Brusnahan; Jered C Garrison
Journal:  Mol Pharm       Date:  2017-03-21       Impact factor: 4.939

Review 2.  Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature.

Authors:  Rubel Chakravarty; Hao Hong; Weibo Cai
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

Review 3.  Degradable vinyl polymers for biomedical applications.

Authors:  Vianney Delplace; Julien Nicolas
Journal:  Nat Chem       Date:  2015-10       Impact factor: 24.427

Review 4.  Design of smart HPMA copolymer-based nanomedicines.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

5.  Combination cytotoxicity of backbone degradable HPMA copolymer gemcitabine and platinum conjugates toward human ovarian carcinoma cells.

Authors:  Acharaporn Duangjai; Kui Luo; Yan Zhou; Jiyuan Yang; Jindřich Kopeček
Journal:  Eur J Pharm Biopharm       Date:  2013-12-04       Impact factor: 5.571

6.  POLYMERIC BIOMATERIALS AND NANOMEDICINES.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  J Drug Deliv Sci Technol       Date:  2015-12-01       Impact factor: 3.981

7.  Biodegradable multiblock poly(N-2-hydroxypropyl)methacrylamide gemcitabine and paclitaxel conjugates for ovarian cancer cell combination treatment.

Authors:  Nate Larson; Jiyuan Yang; Abhijit Ray; Darwin L Cheney; Hamidreza Ghandehari; Jindřich Kopeček
Journal:  Int J Pharm       Date:  2013-07-01       Impact factor: 5.875

8.  Gold nanorod-mediated hyperthermia enhances the efficacy of HPMA copolymer-90Y conjugates in treatment of prostate tumors.

Authors:  Brandon Buckway; Nick Frazier; Adam J Gormley; Abhijit Ray; Hamidreza Ghandehari
Journal:  Nucl Med Biol       Date:  2013-12-10       Impact factor: 2.408

9.  N-(2-Hydroxypropyl)methacrylamide Copolymer-Drug Conjugates for Combination Chemotherapy of Acute Myeloid Leukemia.

Authors:  Rui Zhang; Jiyuan Yang; Yan Zhou; Paul J Shami; Jindřich Kopeček
Journal:  Macromol Biosci       Date:  2015-07-29       Impact factor: 4.979

Review 10.  Macromolecular therapeutics.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  J Control Release       Date:  2014-04-18       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.